GUALBERTO RUANO

Summary

Publications

  1. pmc Physiogenomic analysis of localized FMRI brain activity in schizophrenia
    Andreas Windemuth
    Genomas, Inc, Hartford, CT, 06106, USA
    Ann Biomed Eng 36:877-88. 2008
  2. doi request reprint Physiogenomic comparison of edema and BMI in patients receiving rosiglitazone or pioglitazone
    GUALBERTO RUANO
    Genomas, Inc, 67 Jefferson St, Hartford, CT, United States
    Clin Chim Acta 400:48-55. 2009
  3. pmc Implementing genotype-guided antithrombotic therapy
    Richard L Seip
    Genomas, Inc, 67 Jefferson Street, Hartford, CT 06106, USA
    Future Cardiol 6:409-24. 2010
  4. pmc Physiogenomic analysis of the Puerto Rican population
    GUALBERTO RUANO
    Genomas Inc, 67 Jefferson Street, Hartford, CT 06106, USA
    Pharmacogenomics 10:565-77. 2009
  5. ncbi request reprint Physiogenomic association of statin-related myalgia to serotonin receptors
    GUALBERTO RUANO
    Genomas, Inc, 67 Jefferson Street, Hartford, Connecticut 06102, USA
    Muscle Nerve 36:329-35. 2007
  6. pmc Physiogenomic analysis of statin-treated patients: domain-specific counter effects within the ACACB gene on low-density lipoprotein cholesterol?
    GUALBERTO RUANO
    Genomas, Inc, 67 Jefferson Street, Hartford, CT 06106, USA
    Pharmacogenomics 11:959-71. 2010
  7. ncbi request reprint Physiogenomic analysis links serum creatine kinase activities during statin therapy to vascular smooth muscle homeostasis
    GUALBERTO RUANO
    Genomas, Inc, 67 Jefferson St, Hartford, CT 06106, USA
    Pharmacogenomics 6:865-72. 2005
  8. ncbi request reprint Apolipoprotein A1 genotype affects the change in high density lipoprotein cholesterol subfractions with exercise training
    GUALBERTO RUANO
    Genomas, Inc, 67 Jefferson Street, Hartford, CT 06106, USA
    Atherosclerosis 185:65-9. 2006
  9. doi request reprint Validation of candidate genes associated with cardiovascular risk factors in psychiatric patients
    Andreas Windemuth
    Genomas, Inc and Genetics Research Center, Hartford Hospital, Hartford, CT 06106, USA
    Prog Neuropsychopharmacol Biol Psychiatry 36:213-9. 2012
  10. pmc Physiogenomic analysis of CYP450 drug metabolism correlates dyslipidemia with pharmacogenetic functional status in psychiatric patients
    GUALBERTO RUANO
    Genomas Inc, Hartford, CT 06106, USA
    Biomark Med 5:439-49. 2011

Research Grants

Detail Information

Publications25

  1. pmc Physiogenomic analysis of localized FMRI brain activity in schizophrenia
    Andreas Windemuth
    Genomas, Inc, Hartford, CT, 06106, USA
    Ann Biomed Eng 36:877-88. 2008
    ..The results of this study support the physiogenomic analysis of neuroimaging data to discover associations between genotype and disease-related phenotypes...
  2. doi request reprint Physiogenomic comparison of edema and BMI in patients receiving rosiglitazone or pioglitazone
    GUALBERTO RUANO
    Genomas, Inc, 67 Jefferson St, Hartford, CT, United States
    Clin Chim Acta 400:48-55. 2009
    ..The balance of efficacy and safety of TZD varies widely from patient to patient. Genetic variability may reveal pathophysiological pathways underlying weight gain associated with TZD therapy and due to adiposity and/or edema...
  3. pmc Implementing genotype-guided antithrombotic therapy
    Richard L Seip
    Genomas, Inc, 67 Jefferson Street, Hartford, CT 06106, USA
    Future Cardiol 6:409-24. 2010
    ..The US FDA-mandated drug labeling recognizes the relevance of genotyping in the selection and dosing of both warfarin and clopidogrel...
  4. pmc Physiogenomic analysis of the Puerto Rican population
    GUALBERTO RUANO
    Genomas Inc, 67 Jefferson Street, Hartford, CT 06106, USA
    Pharmacogenomics 10:565-77. 2009
    ..This research was aimed at determining the frequencies of SNPs in key physiological, pharmacological and biochemical genes to infer population structure and ancestry in the Puerto Rican population...
  5. ncbi request reprint Physiogenomic association of statin-related myalgia to serotonin receptors
    GUALBERTO RUANO
    Genomas, Inc, 67 Jefferson Street, Hartford, Connecticut 06102, USA
    Muscle Nerve 36:329-35. 2007
    ..Individual differences in pain perception and nociception related to specific serotonergic gene variants may affect the development of myalgia in statin-treated patients...
  6. pmc Physiogenomic analysis of statin-treated patients: domain-specific counter effects within the ACACB gene on low-density lipoprotein cholesterol?
    GUALBERTO RUANO
    Genomas, Inc, 67 Jefferson Street, Hartford, CT 06106, USA
    Pharmacogenomics 11:959-71. 2010
    ..We hypothesized novel genetic underpinnings for variation in LDLC levels in the context of statin therapy...
  7. ncbi request reprint Physiogenomic analysis links serum creatine kinase activities during statin therapy to vascular smooth muscle homeostasis
    GUALBERTO RUANO
    Genomas, Inc, 67 Jefferson St, Hartford, CT 06106, USA
    Pharmacogenomics 6:865-72. 2005
    ....
  8. ncbi request reprint Apolipoprotein A1 genotype affects the change in high density lipoprotein cholesterol subfractions with exercise training
    GUALBERTO RUANO
    Genomas, Inc, 67 Jefferson Street, Hartford, CT 06106, USA
    Atherosclerosis 185:65-9. 2006
    ..3+/-6.6 mg/dL versus 4.7+/-1.2 mg/dL, p<0.005). These results show that genetic variation at the APOA1 gene promoter is associated with HDL subfraction redistribution resulting from exercise training...
  9. doi request reprint Validation of candidate genes associated with cardiovascular risk factors in psychiatric patients
    Andreas Windemuth
    Genomas, Inc and Genetics Research Center, Hartford Hospital, Hartford, CT 06106, USA
    Prog Neuropsychopharmacol Biol Psychiatry 36:213-9. 2012
    ..We confirmed 8 of the 13 candidate genes at the 95% confidence level. An increased genetic effect size was observed for triglycerides in the psychiatric population compared to that in the cardiovascular population...
  10. pmc Physiogenomic analysis of CYP450 drug metabolism correlates dyslipidemia with pharmacogenetic functional status in psychiatric patients
    GUALBERTO RUANO
    Genomas Inc, Hartford, CT 06106, USA
    Biomark Med 5:439-49. 2011
    ....
  11. doi request reprint Length of psychiatric hospitalization is correlated with CYP2D6 functional status in inpatients with major depressive disorder
    GUALBERTO RUANO
    Genetics Research Center, Hartford Hospital, 67 Jefferson Street, Hartford, CT 06106, USA
    Biomark Med 7:429-39. 2013
    ..This study aimed to determine the effect of the CYP2D6 genotype on the length of hospitalization stay for patients treated for major depressive disorder...
  12. pmc CYP2C9 and VKORC1 genotypes in Puerto Ricans: A case for admixture-matching in clinical pharmacogenetic studies
    David Villagra
    Laboratory of Personalized Health, Genomas, Inc, Hartford, CT 06106, USA
    Clin Chim Acta 411:1306-11. 2010
    ..Accordingly, this study is aimed at investigating whether a correlation between overall genetic similarity and CYP2C9 and/or VKORC1 genotypes could be established...
  13. pmc Mechanisms of statin-induced myalgia assessed by physiogenomic associations
    GUALBERTO RUANO
    Genetics Research Center, Hartford Hospital, Hartford, CT, USA
    Atherosclerosis 218:451-6. 2011
    ..We investigated genetic variants predictive of muscular side effects in patients treated with statins. We utilized a physiogenomic approach to prototype a multi-gene panel correlated with statin-induced myalgia...
  14. pmc Novel drug metabolism indices for pharmacogenetic functional status based on combinatory genotyping of CYP2C9, CYP2C19 and CYP2D6 genes
    David Villagra
    Genomas Inc, Hartford, CT, USA
    Biomark Med 5:427-38. 2011
    ..Each index considers all three genes as complementary components of a liver enzyme drug metabolism system and uniquely benchmarks innate hepatic drug metabolism reserve or alteration through CYP450 combinatory genotype scores...
  15. ncbi request reprint CYP2C19 genotype-guided antiplatelet therapy in a patient with clopidogrel resistance
    Mridula Rai
    Hartford Hospital, Hartford, USA
    Conn Med 76:267-72. 2012
    ..A medication switch to prasugrel,which does not rely on activation by the 2C19 enzyme, reduced platelet reactivity by 86%. The patient has suffered no cardiovascular events in the 18 months since initiation of prasugrel therapy...
  16. doi request reprint Guidance of pharmacotherapy in a complex psychiatric case by CYP450 DNA typing
    Joan Landino
    Integrated Psychiatric Services, Inc, North Haven, Connecticut, USA
    J Am Acad Nurse Pract 23:459-63. 2011
    ..To illustrate the utility of CYP450 genotyping to guide clinical psychopharmacological treatment decisions and minimize or avoid harmful and costly adverse drug reactions (ADRs)...
  17. pmc Genetic associations of brain structural networks in schizophrenia: a preliminary study
    Kanchana Jagannathan
    Olin Neuropsychiatry Research Center, Institute of Living Hartford Hospital, Hartford, Connecticut 06106, USA
    Biol Psychiatry 68:657-66. 2010
    ..We used structural parameters as potential intermediate illness markers to investigate genomic factors derived from single nucleotide polymorphism (SNP) arrays...
  18. ncbi request reprint Somatic complications of psychotropic medications in a patient with multiple CYP2 drug metabolism deficiencies
    GUALBERTO RUANO
    Genomas Inc, Hartford, USA
    Conn Med 71:197-200. 2007
    ..DNA typing for multigene CYP2 deficiencies is diagnostically useful in individuals with histories of multiple ADRs, which could be avoided by DNA-guided individualized prescription...
  19. doi request reprint On naturalistic pharmacogenetic studies: reply from the authors
    Richard L Seip
    Genetics Research Center, Hartford Hospital, Hartford, CT 06106, USA
    Biomark Med 7:917-8. 2013
    ..A letter in response to: RuaƱo G, Szarek BL, Villagra D et al. Length of psychiatric hospitalization is correlated with CYP2D6 functional status in inpatients with major depressive disorder. Biomarkers Med. 7(3), 429-439 (2013). ..
  20. pmc Physiogenomic comparison of human fat loss in response to diets restrictive of carbohydrate or fat
    Richard L Seip
    Genomas, Inc, 67 Jefferson St, Hartford, Connecticut, USA
    Nutr Metab (Lond) 5:4. 2008
    ..We used physiogenomics to explore associations among polymorphisms in candidate genes and changes in relative body fat (Delta%BF) to low fat and low carbohydrate diets...
  21. ncbi request reprint Pharmacogenomic data submissions to the FDA: clinical pharmacology case studies
    GUALBERTO RUANO
    Genomas LLC, New Haven, CT, USA
    Pharmacogenomics 5:513-7. 2004
  22. ncbi request reprint DNA collage and personalized medicine
    GUALBERTO RUANO
    Genomas, USA
    Conn Med 72:322. 2008
  23. ncbi request reprint The pharmacogenomics of warfarin (Coumadin) administration
    GUALBERTO RUANO
    Laboratory of Personalized Health, Genomas, USA
    Conn Med 70:251-2. 2006
  24. ncbi request reprint Evaluation of a point-of-care assay for cardiac markers for patients suspected of acute myocardial infarction
    Alan H B Wu
    Department of Pathology and Laboratory Medicine, Hartford Hospital, 80 Seymour St, Hartford, CT 06102, USA
    Clin Chim Acta 346:211-9. 2004
    ..With new rapid ED assessment protocols, there is increasing pressure to produce results with a short turnaround time (TAT), and point-of-care (POC) testing is one alternative for providing fast results...

Research Grants5

  1. Physiogenomic Arrays for Clinical Neuropsychiatry
    GUALBERTO RUANO; Fiscal Year: 2006
    ..The program will develop NeuroPsych Gene Array products as a new tool for systems understanding of neuropsychiatric and neurodegenerative diseases leading to early diagnosis and personalized therapy. ..
  2. DNA Diagnostics for Minimizing Metabolic Side-Effects of Antipsychotics
    GUALBERTO RUANO; Fiscal Year: 2007
    ..The products will enable DNA- guided medicine: the determination of which AAP is most suitable and the implementation of clinical safeguards, individualized to each patient, using his/her personal genome. ..